New pill hopes to stall prostate cancer when other treatments stop working

NCT ID NCT06568562

Recruiting now Disease control Sponsor: University of Utah Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This phase 2 study tests an oral drug called XL092 (Zanzalintinib) in 32 men with metastatic castration-resistant prostate cancer that has worsened after treatment with Lu-PSMA-617. Participants take one tablet daily at home. The main goal is to see how many men have their cancer stop growing after 16 weeks. Researchers will also monitor side effects and how well the drug works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: XL092 (Zanzalintinib) tablet taken once daily by mouth
What this could lead to: If it works, this could offer a new oral treatment option for men with advanced prostate cancer who have stopped responding to a previous therapy.
What could go wrong: This is a small, early-phase study with only 32 participants, so results may not apply to everyone. The drug may cause side effects or fail to control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Huntsman Cancer Institute at University of Utah
RECRUITING

Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.